Allergenis has a patent-protected food allergy diagnostic platform with 93% accuracy, targeting the growing food allergy market. They have partnered with global therapeutic companies and have a strong team with a track record of success in diagnostic product development.
Revenue Amount
$74,140,000,000
Organizations Involved
Mount Sinai Innovation Partners (MSIP)
Founders
James A. Garner, Albert A. Luderer, Hugh A. Sampson
Company Description
Allergenis is a develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose food allergy.